Second Round of Late-Breaking Clinical Trial Results Announced at VIVA22
VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of three Late-Breaking Clinical Trials sessions at the VIVA22 conference, hosted at Wynn Las Vegas
LAS VEGAS, Nov. 1, 2022 /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of three Late-Breaking Clinical Trials sessions at the VIVA22 conference, hosted at Wynn Las Vegas.
VIVA (Vascular InterVentional Advances) is an annual vascular education symposium that brings together a global, multispecialty faculty to present a variety of talks and live case presentations from clinical centers around the world. Attendees include an audience of interventional cardiologists, interventional radiologists, vascular surgeons, and endovascular medicine specialists. Below are summaries of this afternoon's 6 late-breaking clinical trial presentations.
Three-Year Results of the GORE® VIABAHN® Stent Graft in the Superficial Femoral Artery for In-Stent Restenosis
Presented by Peter A. Soukas, MD
The RELINE MAX study is the first report of long-term, 36-month outcomes of the postmarket approval study of the Gore VIABAHN endoprosthesis (Gore & Associates) for the treatment of bare-metal in-stent restenosis (ISR) in the superficial femoral artery (SFA).
